Announcing Gordian Biotechnology as Tier 5 Sponsor of ARDD 2025

(Press-News.org) The University of Copenhagen is excited to announce Gordian Biotechnology as a Tier 5 Sponsor of the 12th Aging Research & Drug Discovery Meeting, the world's largest conference on aging research in the biopharmaceutical industry that will transpire on August 25 - August 29, 2025 on-site at the Ceremonial Hall, University of Copenhagen, and online. 

Gordian Biotechnology is a therapeutics company transforming how the industry discovers and develops treatments for age-related diseases. By integrating pooled screening in naturally occurring disease models, single-cell analysis, and in vivo gene therapy, Gordian enables early evaluation of therapeutic candidates in complex, physiologically relevant disease models. 

Traditional discovery approaches often rely on reductionist systems that fail to predict clinical success. Gordian’s platform brings the fidelity of whole-organism biology into the earliest phases of drug discovery, making it possible to identify targets with a higher likelihood of success in patients. 

Their lead program in osteoarthritis has demonstrated therapeutic effects on both cartilage degradation and pain across four species including human systems, and is moving towards clinical trials. Additional programs in heart failure, obesity, and pulmonary fibrosis are progressing through preclinical validation of screen hits. 

While gene therapy powers its discovery engine, Gordian advances targets using the modality best suited to the biology of each program. This flexibility supports both internal development and partnerships with biopharma collaborators across a variety of therapeutic approaches. 

At ARDD, Gordian will highlight recent progress across its pipeline, share insights into its discovery platform, and connect with potential partners working to address the unmet needs of aging-related disease. 

 

To learn more, visit gordian.bio. 

ARDD has grown to become the largest and most important conference in longevity biotechnology. Each year, ARDD brings together a unique mix of academic luminaries, biotech innovators, investors, top pharmaceutical executives, physicians, and related health care professionals to discuss the latest advancements in aging research and the event provides unique opportunities to connect with brilliant minds, fostering collaboration and showcasing groundbreaking research in the field.

“We are extremely honored to host Professors Meldal and Levitt at ARDD2025. Their Nobel prize winning discoveries have been instrumental for drug development and molecular design in part through modelling of proteins and molecules, and in part through the ability to easily create new molecules. It is therefore a great pleasure that they are joining our conference.” said Morten Scheibye-Knudsen, MD, Ph.D., University of Copenhagen.

“We are really excited for ARDD2025, especially with Nobel Laureates Morten Meldal and Michael Levitt joining us. Their groundbreaking contributions have had a lasting impact on drug discovery, and having them at the conference is sure to make it an unforgettable experience.” said Daniela Bakula, Ph.D., University of Copenhagen.

“For 12 years, the Aging Research and Drug Discovery (ARDD) forum grew in size and in quality. It became the world’s main platform for academia-pharma-startup-investor partnership and dialogue. In 2025, the conference will feature the Nobel laureates, pharmaceutical industry executives and healthcare delivery leaders. ARDD is a unique platform for advancing longevity biotechnology around the world.” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine. 

“At ARDD we strive to highlight the cutting-edge research and clinical applications in a new discipline of healthy longevity medicine. Having Nobel laureates join and speak at the ARDD conference underscores the critical importance of grounding longevity science and medicine in evidence-based, scientifically rigorous approaches.” said Prof.Dr.Evelyne Bischof, the organizer of the Longevity Medicine Days.

Aging research has become a great platform for advancing drug discovery with blockbuster potential, with pharmaceutical leaders like Novartis, Biogen, and Eli Lilly actively supporting this transformative field. ARDD has established itself as the go-to venue where scientists and pharma companies collaborate, share insights, and launch aging-focused research initiatives. In 2024, industry leaders such as Eli Lilly, Novartis, Regeneron, Biogen, and Lundbeck presented their latest research at ARDD, highlighting the meeting's pivotal role in advancing healthspan and longevity science. Be part of ARDD 2025 and contribute to shaping the future of medicine.

For further information, images or interviews, please contact:

ardd@pharma.ai

About Aging Research for Drug Discovery Conference

At ARDD, leaders in the aging, longevity, and drug discovery field will describe the latest progress in the molecular, cellular and organismal basis of aging and the search for interventions. Furthermore, the meeting will include opinion leaders in AI to discuss the latest advances of this technology in the biopharmaceutical sector and how this can be applied to interventions. Notably, this year we will have a special day called Longevity Medicine Day, specifically for physicians where the leading-edge knowledge of clinical interventions for healthy longevity will be described. ARRD intends to bridge clinical, academic and commercial research and foster collaborations that will result in practical solutions to one of humanity's most challenging problems: aging. Our quest to extend the healthy lifespan of everyone on the planet.

 

END